RNA Constructs for Cross-Reactive HPV Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for persistent cervical HPV infections and low-grade HPV lesions, particularly those caused by high-risk HPV types, leading to ongoing health concerns and anxiety due to the risk of progression to cervical cancer.
Innovation Solution
Development of RNA constructs encoding antigenic HPV polypeptides from multiple high-risk HPV types, specifically designed to induce a cross-reactive immune response, which are administered using non-viral delivery systems such as submicron cationic oil-in-water emulsions or liposomes to target HPV-related conditions like CIN1 and LSIL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for persistent cervical HPV infections, then treatment administration is simple, but treatment effectiveness is insufficient
Solution Approach 1:
The patent changes the molecular parameters of the treatment by using RNA constructs with specific nucleic acid sequences encoding multiple HPV antigens (E1, E2, E6, E7 proteins from high-risk types 16, 18, 31, 33, 35, 39, 45, 52, 58). This molecular reconfiguration enables cross-reactive immune responses against multiple HPV types simultaneously, improving treatment effectiveness without requiring complex multi-drug regimens
Solution Approach 2:
The RNA construct serves multiple functions: it encodes antigens from nine different high-risk HPV types, induces cross-reactive T-cell responses, and provides broad protective coverage. This multi-functionality allows a single treatment formulation to address diverse HPV infections, improving reliability while maintaining treatment simplicity
2Adaptability or versatility
If RNA constructs encoding multiple HPV antigens are used, then cross-reactive immunity is induced, but manufacturing complexity increases
Solution Approach 1:
The patent merges the coding sequences for multiple HPV antigens (E1, E2, E6, E7 from types 16, 18, 31, 33, 35, 39, 45, 52, 58) into a single RNA construct. This consolidation allows simultaneous expression of multiple antigens in one formulation, achieving broad cross-reactive immunity coverage while simplifying the manufacturing process compared to producing separate antigen preparations
Solution Approach 2:
The RNA construct is segmented into distinct coding regions for different HPV antigens, with specific nucleic acid sequences that can be independently designed and optimized. This segmentation allows modular manufacturing and facilitates the incorporation of multiple antigens without proportionally increasing manufacturing complexity
3Reliability
If non-viral delivery systems are used for RNA constructs, then safety is improved, but delivery efficiency decreases
Solution Approach 1:
The patent employs non-viral delivery systems (such as liposomes, polymeric carriers, or nucleic acid-based carriers) as intermediaries to transport the RNA construct to target cells. These delivery vehicles protect the RNA from degradation, facilitate cellular uptake, and enable safe administration without the immunogenicity associated with viral vectors, while maintaining adequate delivery efficiency through optimized carrier design
Data Source
AI summary
Nucleotide constructs encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, immunogenic compositions comprising such constructs and a pharmaceutically acceptable carrier, and uses thereof.